2102 related articles for article (PubMed ID: 15057428)
1. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
[TBL] [Abstract][Full Text] [Related]
2. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part II: radiobiological and immunologic strategies].
Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
Strahlenther Onkol; 2004 Jun; 180(6):331-9. PubMed ID: 15175867
[TBL] [Abstract][Full Text] [Related]
3. T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance.
Cohen PA; Peng L; Kjaergaard J; Plautz GE; Finke JH; Koski GK; Czerniecki BJ; Shu S
Crit Rev Immunol; 2001; 21(1-3):215-48. PubMed ID: 11642606
[TBL] [Abstract][Full Text] [Related]
4. Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts).
Gattoni A; Parlato A; Vangieri B; Bresciani M; Derna R
Clin Ter; 2006; 157(4):377-86. PubMed ID: 17051976
[TBL] [Abstract][Full Text] [Related]
5. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer.
Tahara H; Lotze MT
Gene Ther; 1995 Mar; 2(2):96-106. PubMed ID: 7719935
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma.
Nakano H; Kishida T; Asada H; Shin-Ya M; Shinomiya T; Imanishi J; Shimada T; Nakai S; Takeuchi M; Hisa Y; Mazda O
J Gene Med; 2006 Jan; 8(1):90-9. PubMed ID: 16097036
[TBL] [Abstract][Full Text] [Related]
8. Endogenous IL-21 restricts CD8+ T cell expansion and is not required for tumor immunity.
Søndergaard H; Coquet JM; Uldrich AP; McLaughlin N; Godfrey DI; Sivakumar PV; Skak K; Smyth MJ
J Immunol; 2009 Dec; 183(11):7326-36. PubMed ID: 19915059
[TBL] [Abstract][Full Text] [Related]
9. The combination of IL-21 and IFN-alpha boosts STAT3 activation, cytotoxicity and experimental tumor therapy.
Eriksen KW; Søndergaard H; Woetmann A; Krejsgaard T; Skak K; Geisler C; Wasik MA; Odum N
Mol Immunol; 2009 Feb; 46(5):812-20. PubMed ID: 18947877
[TBL] [Abstract][Full Text] [Related]
10. Molecular immunological approaches to biotherapy of human cancers--a review, hypothesis and implications.
Becker Y
Anticancer Res; 2006; 26(2A):1113-34. PubMed ID: 16619514
[TBL] [Abstract][Full Text] [Related]
11. Biologic therapy of melanoma with cytokines and lymphocytes.
Bear HD; Hamad GG; Kostuchenko PJ
Semin Surg Oncol; 1996; 12(6):436-45. PubMed ID: 8914208
[TBL] [Abstract][Full Text] [Related]
12. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
13. IL-21: a novel IL-2-family lymphokine that modulates B, T, and natural killer cell responses.
Habib T; Nelson A; Kaushansky K
J Allergy Clin Immunol; 2003 Dec; 112(6):1033-45. PubMed ID: 14657853
[TBL] [Abstract][Full Text] [Related]
14. [Antitumor immunity and cellular cancer therapies].
Catros-Quemener V; Bouet F; Genetet N
Med Sci (Paris); 2003 Jan; 19(1):43-53. PubMed ID: 12836191
[TBL] [Abstract][Full Text] [Related]
15. NK cell depletion results in accelerated tumor growth and attenuates the antitumor effect of total body irradiation.
Miller GM; Andres ML; Gridley DS
Int J Oncol; 2003 Dec; 23(6):1585-92. PubMed ID: 14612930
[TBL] [Abstract][Full Text] [Related]
16. The immunoregulatory effects of gangliosides involve immune deviation favoring type-2 T cell responses.
Crespo FA; Sun X; Cripps JG; Fernandez-Botran R
J Leukoc Biol; 2006 Mar; 79(3):586-95. PubMed ID: 16415169
[TBL] [Abstract][Full Text] [Related]
17. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
18. [Molecular bases of cancer immunology].
Barrera-Rodríguez R; Peralta-Zaragoza O; Madrid-Marina V
Salud Publica Mex; 1995; 37(4):344-53. PubMed ID: 7502157
[TBL] [Abstract][Full Text] [Related]
19. Tumor associated antigen and interleukin-12 mRNA transfected dendritic cells enhance effector function of natural killer cells and antigen specific T-cells.
Bontkes HJ; Kramer D; Ruizendaal JJ; Meijer CJ; Hooijberg E
Clin Immunol; 2008 Jun; 127(3):375-84. PubMed ID: 18358784
[TBL] [Abstract][Full Text] [Related]
20. Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells.
Zeng Y; Huebener N; Fest S; Weixler S; Schroeder U; Gaedicke G; Xiang R; Schramm A; Eggert A; Reisfeld RA; Lode HN
Cancer Res; 2007 Mar; 67(5):2331-8. PubMed ID: 17332365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]